BioCryst Pharmaceuticals Inc
BCRX
查看详细走势图
9.400USD
-0.260-2.69%
收盘 03/25, 16:00（美东）报价延迟15分钟
462.06M总市值
7.48市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.69%
5天
+2.62%
1月
+24.50%
6月
+22.88%
今年开始到现在
+20.51%
1年
+16.48%
查看详细走势图
TradingKey BioCryst Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-03-25操作建议
BioCryst Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名1/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价21.30。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioCryst Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
BioCryst Pharmaceuticals Inc亮点
亮点风险
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
业绩高增长
公司营业收入稳步增长，连续3年增长163.97%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值7.48，处于3年历史高位
机构加仓
最新机构持股213.88M股，环比增加6.83%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值114.54K
分析师目标
根据
10
位分析师
买入
评级
21.300
目标均价
+117.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioCryst Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioCryst Pharmaceuticals Inc简介
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
公司代码BCRX
公司BioCryst Pharmaceuticals Inc
CEOGayer (Charles K)
网址https://www.biocryst.com/
相关品种
